Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | PAM | P19021 | 2/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753939 | 0.94 | NAAA (0.46) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL16693727 | 0.91 | DGKA (0.55) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL17753911 | 0.88 | DGKA (0.45) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL11329487 | 0.87 | DGKA (0.67) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL11345638 | 0.87 | DGKA (0.67) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL11344752 | 0.87 | DGKA (0.67) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL11336270 | 0.87 | DGKA (0.67) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL10946414 | 0.86 | DGKA (0.65) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL10948667 | 0.86 | DGKA (0.65) | DGKANAAAHTR2CALDH1A1DNM1 | |
| SCHEMBL10945189 | 0.86 | DGKA (0.65) | DGKANAAAHTR2CALDH1A1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYDEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | CYDEX PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | KIORA PHARMACEUTICALS PTY LTD (AU) | 2024-10-31 | — | — | US | disclosed |
| US-20230357451-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-11-09 | — | — | US | disclosed |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | CYDEX PHARMACEUTICALS, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3183295-B1 | FRACTIONATED ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CYDEX PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230002513-A1 | ALKYLATED CYCLODEXTRIN COMPOSITIONS AND PROCESSES FOR PREPARING AND USING THE SAME | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| EP-4083075-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CyDex Pharmaceuticals, Inc. (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20220332853-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-20 | — | — | US | disclosed |
| CN-112239466-B | Succinate salt of a selective CDK4/6 inhibitor and crystalline forms thereof | 常州千红生化制药股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| CN-112239466-A | Succinate salt of a selective CDK4/6 inhibitor and crystalline forms thereof | 常州千红生化制药股份有限公司 | 2021-01-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358544-A1 | METHOD OF TREATING VISION LOSS IN A HUMAN SUBJECT WITH PHOTOREACTIVE COMPOUNDS | PDE6C, ALDH1A2, PDE6D | DGKA 3306/4885NAAA 1990/4885HTR2C 1554/4885 |
| US-20260115157-A1 | FORMULATIONS CONTAINING ACETAMINOPHEN AND SULFOALKYL ETHER CYCLODEXTRIN | CYP2C8, CYP3A43, SULT2A1 | DGKA 4708/4885NAAA 2512/4885HTR2C 1460/4885 |
| US-11795241-B2 | Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same | AGPS, DDOST, ALG1 | DGKA 599/4885NAAA 3265/4885HTR2C 4682/4885 |
| US-12527755-B2 | Formulations containing acetaminophen and sulfoalkyl ether cyclodextrin | TPMT, GSTP1, ALB | DGKA 4811/4885NAAA 4043/4885HTR2C 730/4885 |
| US-20220332853-A1 | MANUFACTURING PROCESS FOR CYCLODEXTRIN DERIVATIVES | DCXR, AGL, OSTC | DGKA 1608/4885NAAA 4419/4885HTR2C 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.